Works matching DE "VEDOLIZUMAB"
Results: 394
Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-α Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany.
- Published in:
- Digestive Diseases, 2020, v. 38, n. 6, p. 466, doi. 10.1159/000506121
- By:
- Publication type:
- Article
Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center.
- Published in:
- Digestive Diseases, 2018, v. 37, n. 1, p. 33, doi. 10.1159/000492322
- By:
- Publication type:
- Article
Emergency colectomy for massive rectal bleeding in a patient with well-controlled ulcerative colitis receiving Vedolizumab.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
COVID-19 Vaccine Booster Dose Willingness among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study.
- Published in:
- Vaccines, 2022, v. 10, n. 8, p. 1166, doi. 10.3390/vaccines10081166
- By:
- Publication type:
- Article
Role of integrin expression in the prediction of response to vedolizumab: A prospective real‐life multicentre cohort study.
- Published in:
- Clinical & Translational Medicine, 2022, v. 12, n. 4, p. 1, doi. 10.1002/ctm2.769
- By:
- Publication type:
- Article
Case report: Induction and maintenance of steroid-free remission with vedolizumab in a case of steroid-dependent autoimmune pancreatitis.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1201363
- By:
- Publication type:
- Article
Successful treatment of a refractory intestinal Behcet's disease with an oncology history by Vedolizumab: a case report and literature review.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1205046
- By:
- Publication type:
- Article
Vedolizumab for acute gastrointestinal graft-versushost disease: A systematic review and meta-analysis.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1025350
- By:
- Publication type:
- Article
A broad cuproptosis landscape in inflammatory bowel disease.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.1031539
- By:
- Publication type:
- Article
Exposure–efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis.
- Published in:
- Expert Review of Clinical Pharmacology, 2024, v. 17, n. 4, p. 403, doi. 10.1080/17512433.2024.2318465
- By:
- Publication type:
- Article
Confocal laser endomicroscopy as predictive biomarker of clinical and endoscopic efficacy of vedolizumab in ulcerative colitis: The DETECT study.
- Published in:
- PLoS ONE, 2024, v. 19, n. 4, p. 1, doi. 10.1371/journal.pone.0298313
- By:
- Publication type:
- Article
An indirect comparison of efficacy including histologic assessment and safety in biologic therapy in ulcerative colitis: Systemic review and network meta-analysis.
- Published in:
- PLoS ONE, 2023, v. 18, n. 11, p. 1, doi. 10.1371/journal.pone.0293655
- By:
- Publication type:
- Article
Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease.
- Published in:
- Therapeutic Advances in Gastroenterology, 2020, v. 13, p. 1, doi. 10.1177/1756284820979765
- By:
- Publication type:
- Article
Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland.
- Published in:
- Therapeutic Advances in Gastroenterology, 2020, v. 13, p. 1, doi. 10.1177/1756284820941179
- By:
- Publication type:
- Article
Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario.
- Published in:
- Therapeutic Advances in Gastroenterology, 2020, v. 13, p. 1, doi. 10.1177/1756284820936536
- By:
- Publication type:
- Article
Could small molecules be used in combination with biologics for inflammatory bowel disease?
- Published in:
- Expert Review of Clinical Immunology, 2022, v. 18, n. 10, p. 991, doi. 10.1080/1744666X.2022.2104713
- By:
- Publication type:
- Article
Differences in Whole-Blood Transcriptional Profiles in Inflammatory Bowel Disease Patients Responding to Vedolizumab Compared with Non-Responders †.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 6, p. 5820, doi. 10.3390/ijms24065820
- By:
- Publication type:
- Article
Article Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease--A Pilot Study.
- Published in:
- International Journal of Molecular Sciences, 2017, v. 18, n. 8, p. 1827, doi. 10.3390/ijms18081827
- By:
- Publication type:
- Article
Vedolizumab.
- Published in:
- Australian Prescriber, 2015, v. 38, n. 6, p. 224
- Publication type:
- Article
Biosimilars in inflammatory bowel disease.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
- Published in:
- Cancer Immunology, Immunotherapy, 2017, v. 66, n. 5, p. 581, doi. 10.1007/s00262-017-1962-6
- By:
- Publication type:
- Article
Vedolizumab: An Emerging Treatment Option for Pediatric Inflammatory Bowel Disease.
- Published in:
- Journal of Pediatric Pharmacology & Therapeutics, 2021, v. 26, n. 8, p. 795, doi. 10.5863/1551-6776-26.8.795
- By:
- Publication type:
- Article
Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn's Disease: A Review of Comparative Effectiveness Studies.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 8, p. 2187, doi. 10.3390/jcm13082187
- By:
- Publication type:
- Article
Incidence and Course of Joint Inflammation Associated with Inflammatory Bowel Disease in Patients Undergoing Treatment with Vedolizumab/Ustekinumab: The VEDUSTAR Study.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 4, p. 1076, doi. 10.3390/jcm13041076
- By:
- Publication type:
- Article
Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 2, p. 365, doi. 10.3390/jcm13020365
- By:
- Publication type:
- Article
Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 13, p. 4488, doi. 10.3390/jcm12134488
- By:
- Publication type:
- Article
Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1408211
- By:
- Publication type:
- Article
Vedolizumab‐induced acne in inflammatory bowel disease.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Acute Chest Pain as an Infusion Reaction to Vedolizumab.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Oxytocin signalling in dendritic cells regulates immune tolerance in the intestine and alleviates DSS-induced colitis.
- Published in:
- Clinical Science, 2021, v. 135, n. 4, p. 597, doi. 10.1042/CS20201438
- By:
- Publication type:
- Article
Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Baseline levels of dynamic CD4<sup>+</sup> T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Vedolizumab in the treatment of Crohn's disease: A promising therapeutic approach.
- Published in:
- Drug Development Research, 2024, v. 85, n. 4, p. 1, doi. 10.1002/ddr.22220
- By:
- Publication type:
- Article
Successful treatment of chronic refractory pouchitis with vedolizumab.
- Published in:
- 2017
- By:
- Publication type:
- Letter
Factors influencing the discontinuation of biologic therapies in patients with ulcerative colitis.
- Published in:
- Journal of Pharmaceutical Health Care & Sciences, 2024, v. 10, n. 1, p. 1, doi. 10.1186/s40780-024-00386-2
- By:
- Publication type:
- Article
Co-Administration of Proton Pump Inhibitors May Negatively Affect the Outcome in Inflammatory Bowel Disease Treated with Vedolizumab.
- Published in:
- Biomedicines, 2024, v. 12, n. 1, p. 158, doi. 10.3390/biomedicines12010158
- By:
- Publication type:
- Article
Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?
- Published in:
- Biomedicines, 2023, v. 11, n. 6, p. 1553, doi. 10.3390/biomedicines11061553
- By:
- Publication type:
- Article
Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review.
- Published in:
- Biomedicines, 2023, v. 11, n. 3, p. 747, doi. 10.3390/biomedicines11030747
- By:
- Publication type:
- Article
Early Clinical Remission Is a Predictor of Long-Term Remission with the Use of Vedolizumab for Ulcerative Colitis.
- Published in:
- Biomedicines, 2022, v. 10, n. 10, p. N.PAG, doi. 10.3390/biomedicines10102526
- By:
- Publication type:
- Article
Plumericin Protects against Experimental Inflammatory Bowel Disease by Restoring Intestinal Barrier Function and Reducing Apoptosis.
- Published in:
- Biomedicines, 2021, v. 9, n. 1, p. 67, doi. 10.3390/biomedicines9010067
- By:
- Publication type:
- Article
Assessment of Vedolizumab Disease‐Drug‐Drug Interaction Potential in Patients With Inflammatory Bowel Diseases.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 7, p. 734, doi. 10.1002/cpdd.891
- By:
- Publication type:
- Article
Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China.
- Published in:
- Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1188751
- By:
- Publication type:
- Article
Expression levels of cellular inhibitor of apoptosis proteins and colitogenic cytokines are inversely correlated with the activation of interferon regulatory factor 4.
- Published in:
- Clinical & Experimental Immunology, 2022, v. 207, n. 3, p. 340, doi. 10.1093/cei/uxac005
- By:
- Publication type:
- Article
Live-attenuated vaccination in patients with inflammatory bowel disease while continuing or after elective switch to vedolizumab.
- Published in:
- Intestinal Research, 2024, v. 22, n. 3, p. 378, doi. 10.5217/ir.2023.00203
- By:
- Publication type:
- Article
Vedolizumab for perianal fistulizing Crohn's disease: systematic review and meta-analysis.
- Published in:
- Intestinal Research, 2022, v. 20, n. 2, p. 240, doi. 10.5217/ir.2021.00091
- By:
- Publication type:
- Article
Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation.
- Published in:
- Intestinal Research, 2022, v. 20, n. 1, p. 114, doi. 10.5217/ir.2021.00037
- By:
- Publication type:
- Article
Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study.
- Published in:
- Intestinal Research, 2022, v. 20, n. 1, p. 72, doi. 10.5217/ir.2020.00117
- By:
- Publication type:
- Article
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis.
- Published in:
- Intestinal Research, 2021, v. 19, n. 4, p. 448, doi. 10.5217/ir.2020.00026
- By:
- Publication type:
- Article
Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis.
- Published in:
- Intestinal Research, 2021, v. 19, n. 1, p. 53, doi. 10.5217/ir.2019.09146
- By:
- Publication type:
- Article